Peter Wehrwein

Japanese researchers say their study suggests that atrial fibrillation may trigger adverse events in HCM patients.

Prices in American healthcare are difficult to nail down because they are obscured by secret negotiations between payers and providers and, in the case of drugs, pharmaceutical manufacturers. But that is beginning to change.

For an assortment of reasons, the federal government hasn’t taken any action on regulating drug prices, so a handful of states have taken matters into their own hands.

In this final part of a three-part video series, Managed Healthcare Executive® Managing Editor Peter Wehrwein recently interviewed Kulleni Gebreyes, M.D., director of Deloitte's new Health Equity Institute about her career, healthcare disparities and equity issues and the work of the institute.

In this second of a three-part video series, Managed Healthcare Executive® Managing Editor Peter Wehrwein recently interviewed Kulleni Gebreyes, M.D., director of Deloitte's new Health Equity Institute about her career, healthcare disparities and equity issues and the work of the institute.

In this first of a three-part video series, Managed Healthcare Executive® Managing Editor Peter Wehrwein recently interviewed Kulleni Gebreyes, M.D., director of Deloitte's new Health Equity Institute about her career, healthcare disparities and equity issues and the work of the institute.

U.S. Preventive Services Task Force (USPSTF) screening recommendations for diabetes, prediabetes need to be coupled with public health measures, argues accompanying editorial.

A wave of vaccine mandates has started. The FDA's full OK today may have an effect on the unvaccinated with a wait-and-see attitude and could, according to one expert, open the door to off-label use of the vaccine by clinicians.

The drug savings and greater use of generics that ACO proponents hope for did not materailize.

The FDA’s controversial approval of Aduhelm (aducanumab) has put a spotlight on the accelerated approval pathway that the agency used to approve the drug.

One-quarter of Medicaid claims result in a denial of payment for at least one service included in the claim compared with just 7.3% of claims submitted to Medicare and 4.8% of claims submitted to commercial insurers

It's rate-setting season for insurers, although the full picture for 2022 premiums won’t emerge for some months yet.

Amida Care’s Doug Wirth says they should work with state-level officials to make sure services are covered after Biden administration’s guidance that coverage is mandatory.

Adam Sabloff, CEO and founder of VirtualHealth, says his father’s watchwords, “if you don’t quit, you’ll win,” have inspired and motivated him throughout a varied career that has had ups and downs.

Wide ranging report covers a lot of ground. It sounds an optimistic note about biosimilars but is critical of white bagging.

Michael Zeglinski, senior vice president and CEO of specialty and infusion pharmacy at OptumRx, has applied the experiences he had playing the French horn in orchestras to his increasingly important roles in healthcare: “Being in an orchestra has its own dynamics — the conductor, being part of a team and doing your best to contribute to the whole. All of that applies to business.”

Study shows that nonsmall cell lung cancer patients who smoke but quit after their diagnosis have better overall survival, progression-free survival than patients who continue to smoke.

VP of social responsibility says the health insurer wants to “broaden our scope a little bit” and factor in community voices.

Some see the upward trend in cancer drug costs as accelerating — and unsustainable. Value-based pathways might rearrange the incentives to put some downward pressure on prices.

Biogen officials defended the company's Alzheimer's drug and criticized ICER's cost-effectiveness report today at a meeting of one of the group's advisory committees. But the committee cast a series of votes that showed the members have a low opinion of the drug.

ICER has entered the fray and is holding virtual public meeting tomorrow.

Harvard clinicians say the case for mandating COVID-19 vaccination is stronger than it is for mandating flu shots — and give eight reasons why

In carpentry, it is best to measure twice and cut once. In cancer clinical trials, it is best to measure patient-reported outcomes uniformly, according to a new draft guidance from the FDA.

Sands ,a medical oncologist who specializes in lung cancer, says the false discovery has been misconstruted as a false positive rate. He also makes a case for early detection and new USPSTF as working to correct disparities.

In this week's episode of "Tuning In to the C-Suite" podcast, Managed Healthcare Executive Senior Editor, Peter Wehrwein and Associate Editor, Briana Contreras, spoke with yet another Editorial Advisory Board Member for a segment of the "Meet the Board" series. The two had the pleasure of chatting with Meg Murray, M.P.A., founding CEO of the Association for Community Affiliated Plans, about her journey in healthcare, her organization and were able to look into some of her views about the ACA, equity and racism in healthcare and the Biden Administration’s effects on healthcare.

In this part three video series, Civica Rx CEO Martin VanTrieste says Civica is launching an outpatient retail market with its first retail drug coming to the market next year.

Study published in the Annals of Internal Medicine elaborates on past positive findings for Zynquista (sotagliflozin), a dual inhibitor of SGLT1 and SGLT2.

Editors of MHE and their furry friends had the pleasure of speaking with Dr. Glenn Levine, professor of medicine at Baylor College of Medicine and chief of the cardiology section at Michael E. DeBakey VA Medical Center in Houston. Dr. Levine is also a volunteer medical expert for the American Heart Association’s Healthy Bond for Life initiative and is lead author of the Association’s Scientific Statement on Pet Ownership and Cardiovascular Risk. In the conversation, Dr. Levine shared some wellbeing tips on how our pets can benefit our mental and physical health and wellbeing.

The American Heart Association statement says people with resistant or poorly control hypertension, pulmonary hypertension and recurrent atrial fibrillation should be screened for obstructive sleep apnea. Although enthusiastic about the future of wearables and other kinds of technology for diagnosing obstructive sleep apnea, the statement also notes that "diagnostic accuracy needs to be better defined."

Results run counter to common beliefs about the effects of self-selection into voluntary value-based payment programs.